JP2024523438A5 - - Google Patents

Info

Publication number
JP2024523438A5
JP2024523438A5 JP2023578700A JP2023578700A JP2024523438A5 JP 2024523438 A5 JP2024523438 A5 JP 2024523438A5 JP 2023578700 A JP2023578700 A JP 2023578700A JP 2023578700 A JP2023578700 A JP 2023578700A JP 2024523438 A5 JP2024523438 A5 JP 2024523438A5
Authority
JP
Japan
Prior art keywords
mol
body weight
total
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523438A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/066764 external-priority patent/WO2022268740A1/en
Publication of JP2024523438A publication Critical patent/JP2024523438A/ja
Publication of JP2024523438A5 publication Critical patent/JP2024523438A5/ja
Pending legal-status Critical Current

Links

JP2023578700A 2021-06-21 2022-06-20 Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン Pending JP2024523438A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163212781P 2021-06-21 2021-06-21
US63/212,781 2021-06-21
US202163257879P 2021-10-20 2021-10-20
US63/257,879 2021-10-20
PCT/EP2022/066764 WO2022268740A1 (en) 2021-06-21 2022-06-20 Combination dosage regime of cd137 and pd-l1 binding agents

Publications (2)

Publication Number Publication Date
JP2024523438A JP2024523438A (ja) 2024-06-28
JP2024523438A5 true JP2024523438A5 (https=) 2025-06-27

Family

ID=82358492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578700A Pending JP2024523438A (ja) 2021-06-21 2022-06-20 Cd137結合物質とpd-l1結合物質の組合せ投薬レジメン

Country Status (8)

Country Link
US (1) US20240262924A1 (https=)
EP (1) EP4359435A1 (https=)
JP (1) JP2024523438A (https=)
BR (1) BR112023027006A2 (https=)
CA (1) CA3223375A1 (https=)
IL (1) IL309319A (https=)
TW (1) TW202315891A (https=)
WO (1) WO2022268740A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
JP2006502091A (ja) 2002-03-01 2006-01-19 イミューノメディクス、インコーポレイテッド クリアランス速度を高めるための二重特異性抗体点変異
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
KR20060041205A (ko) 2003-07-01 2006-05-11 이뮤노메딕스, 인코오포레이티드 양특이성 항체들의 다가 담체들
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010059315A1 (en) 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
PT3514172T (pt) 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
SI3242890T1 (sl) 2015-01-08 2020-01-31 BioNTech SE Agonistična sredstva, ki vežejo receptorje TNF
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof

Similar Documents

Publication Publication Date Title
JP2022050522A (ja) 癌の治療のための併用療法
US20240075133A1 (en) Methods and compositions for reduction of immunogenicity
JP2024525758A5 (https=)
WO2020169062A1 (zh) 抗pd-l1抗体及其用途
CN118201613A (zh) 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
JP2023551980A5 (https=)
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2024536383A5 (https=)
JP2024523438A5 (https=)
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
TW202545570A (zh) 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
CN119587691A (zh) 抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤
CN115087461A (zh) 使用pd-1拮抗剂、ilt4拮抗剂和化学治疗剂的组合治疗癌症的方法
JP2024538755A5 (https=)
JP2022548881A5 (https=)
CN120344271A (zh) 抗her2抗体药物偶联物治疗乳腺癌
TW202143969A (zh) 抗pd-1抗體和多受體酪胺酸激酶抑制劑的藥物組合及其使用方法
TW202114663A (zh) EZH2抑制劑與含有TGF-β受體的融合蛋白聯合在製備治療腫瘤的藥物中的用途
US20250011453A1 (en) Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
US20220259316A1 (en) Multiple-Variable Dosage Regimen for the Treatment of Cancers with High Expression of EGFR
WO2026021442A1 (zh) 抗体药物偶联物在制备治疗肺癌的药物中的用途
WO2026026912A1 (zh) 抗体药物偶联物和抗vegf抗体的联合应用
TW202446792A (zh) 使用可活化抗ctla4抗體與pembrolizumab組合治療癌症之方法